Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tanezumab - Eli Lilly/Pfizer

Drug Profile

Tanezumab - Eli Lilly/Pfizer

Alternative Names: PF-04383119; PF-4383119; RI-624; RN-624

Latest Information Update: 11 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rinat Neuroscience
  • Developer Pfizer
  • Class Monoclonal antibodies; Non-opioid analgesics
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Back pain; Cancer pain; Musculoskeletal pain
  • Phase II Pain
  • Suspended Diabetic neuropathies
  • No development reported Postherpetic neuralgia

Most Recent Events

  • 29 Jan 2019 Efficacy and adverse events data from a phase III trial in Musculoskeletal pain released by Pfizer and Eli Lilly
  • 20 Dec 2018 Pfizer and Eli Lilly complete the phase III TANGO trial in Back pain in USA, Canada, Denmark, France, Hungary, Japan, South Korea, Spain and Sweden (SC) (NCT02528253)
  • 01 Dec 2018 Pfizer completes a phase III trial for Musculoskeletal pain in Austria, Finland, Germany, Japan, Poland, Slovakia, Spain, the UK, Hungary, Sweden, Bulgaria, Portugal, France, Italy and Romania (SC) (NCT02709486)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top